The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation.
Alessandro Maloberti, Alessandro Mengozzi, Elisa Russo, Arrigo Francesco Giuseppe Cicero, Fabio Angeli, Enrico Agabiti Rosei, Carlo Maria Barbagallo, Bruno Bernardino, Michele Bombelli, Federica Cappelli, Edoardo Casiglia, Rosario Cianci, Michele Ciccarelli, Massimo Cirillo, Pietro Cirillo, Giovambattista Desideri, Lanfranco D'Elia, Raffaella Dell'Oro, Rita Facchetti, Claudio Ferri, Ferruccio Galletti, Cristina Giannattasio, Loreto Gesualdo, Guido Iaccarino, Luciano Lippa, Francesca Mallamaci, Stefano Masi, Maria Masulli, Alberto Mazza, Maria Lorenza Muiesan, Pietro Nazzaro, Gianfranco Parati, Paolo Palatini, Paolo Pauletto, Roberto Pontremoli, Nicola Riccardo Pugliese, Fosca Quarti-Trevano, Marcello Rattazzi, Gianpaolo Reboldi, Giulia Rivasi, Massimo Salvetti, Valerie Tikhonoff, Giuliano Tocci, Andrea Ungar, Paolo Verdecchia, Francesca Viazzi, Massimo Volpe, Agostino Virdis, Guido Grassi, Claudio Borghi
{"title":"The Results of the URRAH (Uric Acid Right for Heart Health) Project: A Focus on Hyperuricemia in Relation to Cardiovascular and Kidney Disease and its Role in Metabolic Dysregulation.","authors":"Alessandro Maloberti, Alessandro Mengozzi, Elisa Russo, Arrigo Francesco Giuseppe Cicero, Fabio Angeli, Enrico Agabiti Rosei, Carlo Maria Barbagallo, Bruno Bernardino, Michele Bombelli, Federica Cappelli, Edoardo Casiglia, Rosario Cianci, Michele Ciccarelli, Massimo Cirillo, Pietro Cirillo, Giovambattista Desideri, Lanfranco D'Elia, Raffaella Dell'Oro, Rita Facchetti, Claudio Ferri, Ferruccio Galletti, Cristina Giannattasio, Loreto Gesualdo, Guido Iaccarino, Luciano Lippa, Francesca Mallamaci, Stefano Masi, Maria Masulli, Alberto Mazza, Maria Lorenza Muiesan, Pietro Nazzaro, Gianfranco Parati, Paolo Palatini, Paolo Pauletto, Roberto Pontremoli, Nicola Riccardo Pugliese, Fosca Quarti-Trevano, Marcello Rattazzi, Gianpaolo Reboldi, Giulia Rivasi, Massimo Salvetti, Valerie Tikhonoff, Giuliano Tocci, Andrea Ungar, Paolo Verdecchia, Francesca Viazzi, Massimo Volpe, Agostino Virdis, Guido Grassi, Claudio Borghi","doi":"10.1007/s40292-023-00602-4","DOIUrl":null,"url":null,"abstract":"<p><p>The relationship between Serum Uric Acid (UA) and Cardiovascular (CV) diseases has already been extensively evaluated, and it was found to be an independent predictor of all-cause and cardiovascular mortality but also acute coronary syndrome, stroke and heart failure. Similarly, also many papers have been published on the association between UA and kidney function, while less is known on the role of UA in metabolic derangement and, particularly, in metabolic syndrome. Despite the substantial number of publications on the topic, there are still some elements of doubt: (1) the better cut-off to be used to refine CV risk (also called CV cut-off); (2) the needing for a correction of UA values for kidney function; and (3) the better definition of its role in metabolic syndrome: is UA simply a marker, a bystander or a key pathological element of metabolic dysregulation?. The Uric acid Right for heArt Health (URRAH) project was designed by the Working Group on uric acid and CV risk of the Italian Society of Hypertension to answer the first question. After the first papers that individuates specific cut-off for different CV disease, subsequent articles have been published responding to the other relevant questions. This review will summarise most of the results obtained so far from the URRAH research project.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/6b/40292_2023_Article_602.PMC10600296.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"High Blood Pressure & Cardiovascular Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40292-023-00602-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 3
Abstract
The relationship between Serum Uric Acid (UA) and Cardiovascular (CV) diseases has already been extensively evaluated, and it was found to be an independent predictor of all-cause and cardiovascular mortality but also acute coronary syndrome, stroke and heart failure. Similarly, also many papers have been published on the association between UA and kidney function, while less is known on the role of UA in metabolic derangement and, particularly, in metabolic syndrome. Despite the substantial number of publications on the topic, there are still some elements of doubt: (1) the better cut-off to be used to refine CV risk (also called CV cut-off); (2) the needing for a correction of UA values for kidney function; and (3) the better definition of its role in metabolic syndrome: is UA simply a marker, a bystander or a key pathological element of metabolic dysregulation?. The Uric acid Right for heArt Health (URRAH) project was designed by the Working Group on uric acid and CV risk of the Italian Society of Hypertension to answer the first question. After the first papers that individuates specific cut-off for different CV disease, subsequent articles have been published responding to the other relevant questions. This review will summarise most of the results obtained so far from the URRAH research project.
期刊介绍：
High Blood Pressure & Cardiovascular Prevention promotes knowledge, update and discussion in the field of hypertension and cardiovascular disease prevention, by providing a regular programme of independent review articles covering key aspects of the management of hypertension and cardiovascular diseases. The journal includes: Invited ''State of the Art'' reviews. Expert commentaries on guidelines, major trials, technical advances.Presentation of new intervention trials design.''Pros and Cons'' or round tables on controversial issues.Statements on guidelines from hypertension and cardiovascular scientific societies.Socio-economic issues.Cost/benefit in prevention of cardiovascular diseases.Monitoring of healthcare systems.News and views from the Italian Society of Hypertension (including abstracts).All manuscripts are subject to peer review by international experts. Letters to the editor are welcomed and will be considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
